Arrowstreet Capital’s Juno Therapeutics, Inc. JUNO Stock Holding History

Arrowstreet Capital’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-132,500	Closed	-$3.98M	–	2876
2016 Q3	$3.98M	Buy	+132,500	New	+$4.12M	0.01%	714
2015 Q3	–	Sell	-49,500	Closed	-$2.64M	–	1582
2015 Q2	$2.64M	Buy	+49,500	New	+$2.63M	0.01%	576

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Arrowstreet Capital's JUNO Position: Q4 2016 in Review

Arrowstreet Capital sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2016, closing a stake of 132,500 shares — an estimated $3.98M sold.

Arrowstreet Capital first reported a position in JUNO in Q2 2015 and held it in 2 quarters. The position peaked at $3.98M in Q3 2016. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

Arrowstreet Capital reported no remaining Juno Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Arrowstreet Capital sold 132,500 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $3.98M.
Arrowstreet Capital first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 2 quarters.
Arrowstreet Capital's Juno Therapeutics, Inc. position peaked at $3.98M in Q3 2016.
159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on Arrowstreet Capital's 13F filing for Q4 2016, filed 15 Feb 2017.